Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
136
resultados
Última actualización
20/08/2025 [07:11:00]
Resumen de: US2025259727A1
Disclosed is a meal detection and meal size estimation machine learning technology. In some embodiments, the techniques entail applying to a trained multioutput neural network model a set of input features, the set of input features representing glucoregulatory management data, insulin on board, and time of day, the trained multioutput neural network model representing multiple fully connected layers and an output layer formed from first and second branches, the first branch providing a meal detection output and the second branch providing a carbohydrate estimation output; receiving from the meal detection output a meal detection indication; and receiving from the carbohydrate estimation output a meal size estimation.
Resumen de: US2025259720A1
This disclosure relates to a method, a mobile device, and a computer program, for managing medical data such as, e.g., glucose concentrations, by an electronic disease management system. In the method a change of the local time between generation of a first set of medical data and a second set of medical data is detected.
Resumen de: US2025255561A1
A method performed by an electronic apparatus is disclosed. The method comprises receiving information about a user's glucose concentration from an analyte monitoring device attached to the user's body, receiving an alert condition set by a follower of the user at the follower's device, determining whether the alert condition is satisfied based on the information about the user's glucose concentration, and controlling the follower's device to output an alert when the alert condition is satisfied.
Resumen de: US2025256027A1
The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include receiving and/or determining one or more user specific dosage parameters.
Resumen de: AU2024219128A1
Disclosed herein are intravascular artificial pancreas devices and methods for their manufacture.
Resumen de: WO2024077303A2
Glucose systems that include a minimally invasive scalp-worn device that includes first and second sensors. The systems are adapted to determine one or more glucose states based on sensed EEG signals using the scalp-worn device.
Resumen de: EP4599866A2
An infusion pump system is disclosed for dispensing liquid medication, such as insulin. The infusion pump system includes a first reservoir for storing liquid medication, a first fluid driver for exerting pressure on the first reservoir, a second reservoir for storing liquid medication, and a second fluid driver for exerting pressure on the second reservoir. One or more valves are used to permit flow of liquid medication from the first reservoir to the second reservoir, and to permit flow of liquid medication from the second reservoir to an infusion site. Each of the valves is selectively opened or closed to fill the second reservoir with liquid medication from the first reservoir and to dispense liquid medication from the second reservoir to the infusion site. A controller and one or more sensors are used to monitor and control the system.
Resumen de: EP4601278A2
Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management.
Resumen de: EP4601218A2
A system is provided for monitoring analyte in a host, including a continuous analyte sensor that produces a data stream indicative of a host's analyte concentration and a device that receives and records data from the data stream from the continuous analyte sensor. In one embodiment, the device includes a single point analyte monitor, from which it obtains an analyte value, and is configured to display only single point analyte measurement values, and not any analyte measurement values associated with data received from the continuous analyte sensor. Instead, data received from the continuous analyte sensor is used to provide alarms to the user when the analyte concentration and/or the rate of change of analyte concentration, as measured by the continuous analyte sensor, is above or below a predetermined range. Data received from the continuous analyte sensor may also be used to prompt the diabetic or caregiver to take certain actions, such as to perform another single point blood glucose measurement. In another embodiment, the device provides for toggling between two modes, with one mode that allows for display of glucose concentration values associated with the continuous glucose sensor and a second mode that prevents the display of glucose concentration values associated with the continuous glucose sensor.
Resumen de: EP4599864A2
Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device (100, 500) to deliver fluid to a body of a user involves obtaining measurement values for a physiological condition influenced by the fluid, autonomously operating the infusion device to deliver the fluid based at least in part on the measurement values, and detecting a nonactionable condition based on the measurement values. In response to detecting the nonactionable condition, delivery of the fluid is limited while maintaining autonomous operation of the infusion device. In one exemplary embodiment, the nonactionable condition is a rescue condition indicative of the user having consumed fast-acting carbohydrates, and thus insulin delivery may be automatically limited in response to detecting the rescue carbohydrate consumption.
Resumen de: US12383675B1
In an aspect, the present disclosure provides a method comprising: (a) positioning an insulin delivery device on a body of a subject via a single puncture site in said body of said subject; (b) using said insulin delivery device to deliver an insulin or insulin analog formulation to said subject via said single puncture site; and (c) using a sensor of said insulin delivery device to measure a glucose concentration in said body of said subject via said single puncture site, wherein (b) and (c) are performed at substantially the same time for a time period of at least 1 hour subsequent to said positioning in (a), while maintaining a sensitivity of said sensor of at least 50% of an initial sensitivity of said sensor.
Resumen de: US2025253045A1
A method of administering insulin includes receiving blood glucose measurements of a patient at a data processing device from a glucometer. Each blood glucose measurement is separated by a time interval and includes a blood glucose time associated with a time of measuring the blood glucose measurement. The method also includes receiving patient information at the data processing device and selecting a subcutaneous insulin treatment for tube-fed patients from a collection of subcutaneous insulin treatments. The selection is based on the blood glucose measurements and the patient information. The subcutaneous insulin treatment program for tube-fed patients determines recommended insulin doses based on the blood glucose times. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment.
Resumen de: US2025249171A1
A variety of location-based and/or proximity-based features related to diabetes management systems can be used to improve maintenance compliance and/or to provide important information to PWD designated assistance entities (e.g., family, friends, givers, HCPs, emergency medicine providers) under certain conditions. In some cases, a user's location can be tracked or determined to trigger and/or time alerts about upcoming maintenance tasks in a way that will increase the likelihood that the PWD will immediately perform the designated maintenance task. In some cases, methods, devices, and systems provided herein can use proximity to non-paired mobile computing devices to deliver data to PWD designated assistance entities.
Resumen de: US2025248624A1
The present invention relates to a system and method for predicting blood glucose levels in a non-invasive manner using deduction learning. The deduction learning (DL) model 10 of the present invention predicts blood glucose level 300 based on the relationship or correlation between blood glucose level variation and PPG signal variation. Specifically, the DL model 10 of the present invention comprises a differential cell 100 (DC) configured to calculate predicted blood glucose level BGpred 300 using two PPG signals Si 200b and Si−1 200a, a BG i−1,ref 230 and relationship or correlation between variances of the two PPG signals and variances of the reference blood glucose level 230 and the predicted blood glucose level 300.
Resumen de: US2025248654A1
Embodiments of the invention provide skin adhesive patches designed to ease a diabetic patient's maneuverability and alignment of a glucose sensing device as the patient adheres the device to their skin. Embodiments of the invention can be adapted for use with a wide variety of medical components that are coupled to the skin of patients, including insulin infusion sets, patch pumps, and all-in-one patch sets.
Resumen de: US2025248633A1
Devices are provided for measurement of an analyte concentration, e.g., glucose in a host. The device can include a sensor configured to generate a signal associated with a concentration of an analyte; and a sensing membrane located over the sensor. The sensing membrane comprises a diffusion resistance domain configured to control a flux of the analyte therethrough. The diffusion resistance domain comprises one or more zwitterionic compounds and a base polymer comprising both hydrophilic and hydrophobic regions.
Resumen de: US2025248627A1
Provided is an implant apparatus for a continuous glucose monitor. The implant apparatus includes a housing assembly and a driving assembly disposed in the housing assembly. The housing assembly includes an outer housing. The outer housing has an opening at an end of the outer housing. The driving assembly has a locked state in which the driving assembly is fixed relative to the outer housing and a triggered state in which the driving assembly is movable towards the opening. The implant apparatus further includes a trigger. The outer housing includes a guiding channel located at a side wall of the outer housing and extending towards the opening. The trigger is movable along the guiding channel towards the opening and has a first position and a second position relative to the outer housing, to enable the driving assembly to switch from the locked state to the triggered state.
Resumen de: WO2025166261A1
A computer implemented method for controlling insulin dosing for a subject includes saving field collected glucose and insulin data for the subject. The method implements a virtual personal model, or digital twin, of the subject by using the field collected data to save electronic field collected traces of blood glucose levels and electronic field collected traces of insulin levels for the subject. A replay phase of the virtual personal model emulates test insulin therapies to generate virtual insulin doses that correspond to the field collected data. The method converges to a result by comparing field collected glucose traces and regenerated glucose traces. This method recommends a basal rate profile for the subject using saved replay data by calculating inversions of the virtual personal model by deconvolution.
Resumen de: WO2025164955A1
Provided is a system for managing blood glucose, the system comprising: a bio-apparatus for measuring biosignals including blood glucose; and a drug injection device for injecting drug for controlling blood glucose in the body, wherein the bio-apparatus and drug injection device are each provided with at least one electrode for connecting to the human body, and transmit and receive electrical signals between each other with the human body as the medium, and the bio-apparatus is provided with a power reception circuit for receiving operational power from the drug injection device.
Resumen de: WO2025161630A1
A Raman spectroscopy-based non-invasive glucose meter, comprising a light source module (110), a dichroic mirror (130), a lens module (150), an optical filter (191), and a photoelectric spectral measurement module (170). The light source module (110), the photoelectric spectral measurement module (170), and the lens module (150) are all arranged to correspond to the dichroic mirror (130). The optical filter (191) is disposed on a light-incident side of the photoelectric spectral measurement module (170) to filter out short-wavelength excitation light, and the photoelectric spectral measurement module (170) obtains spectral information by changing the refractive index in its own material.
Resumen de: US2025249170A1
A variety of location-based and/or proximity-based features related to diabetes management systems can be used to improve maintenance compliance and/or to provide important information to PWD designated assistance entities (e.g., family, friends, givers, HCPs, emergency medicine providers) under certain conditions. In some cases, a user's location can be tracked or determined to trigger and/or time alerts about upcoming maintenance tasks in a way that will increase the likelihood that the PWD will immediately perform the designated maintenance task. In some cases, methods, devices, and systems provided herein can use proximity to non-paired mobile computing devices to deliver data to PWD designated assistance entities.
Resumen de: US2025248667A1
An artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient. Aspects of the present disclosure provide for a system and method for configuring one or more clinical algorithms according to one or more clinical protocols to configure a conversational AI model. The conversational AI model is configured to drive a conversational AI agent configured to facilitate a plurality of multi-turn conversational interactions between a patient user and the conversational agent to enable automated initiation and titration of one or more diabetes medications for the patient.
Resumen de: US2025248666A1
An artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient. Aspects of the present disclosure provide for a system and method for configuring one or more clinical algorithms according to one or more clinical protocols to configure a conversational AI model. The conversational AI model is configured to drive a conversational AI agent configured to facilitate a plurality of multi-turn conversational interactions between a patient user and the conversational agent to enable automated initiation and titration of one or more diabetes medications for the patient.
Resumen de: MX2025008037A
Systems and methods for monitoring glucose variability are described. Data indicative of glucose levels of the subject is received. A first glucose metric is determined in a first time period. A second glucose metric is determined in a second time period. A difference between the second and first glucose metrics are determined. The difference is compared to a threshold. A first indicator is displayed if the difference does not exceed the threshold and a second indicator is displayed if the difference exceeds the threshold. In some embodiments, the indicator is one of a balanced state or a steady state and the second indicator is one of an unbalanced state, an unsteady state, a not steady state, or a spiky state.
Nº publicación: WO2025159222A1 31/07/2025
Solicitante:
SUNGKWANG MEDICAL FOUND [KR]
\uC758\uB8CC\uBC95\uC778 \uC131\uAD11\uC758\uB8CC\uC7AC\uB2E8
Resumen de: WO2025159222A1
The present disclosure relates to a method and a device for predicting the risk of gestational diabetes by using an artificial intelligence model. An embodiment of the present disclosure may provide a method for predicting the risk of gestational diabetes by using an artificial intelligence model, the method comprising the steps of: inputting data on a mother to a gestational diabetes prediction model generated on the basis of a training data set; and obtaining the incidence rate of gestational diabetes from the gestational diabetes prediction model, wherein the data on the mother includes a final variable determined from multiple initial variables of the training data set.
BOPI
Sede Electrónica
